

SETTING THE SCENE:



PHILIPPE AMOUYEL

French Foundation of Scientific Co-operation in
Alzheimer's Disease, France




EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE



VISION EUROPE 2030

**Bridging the Innovation Gap: Precision
Neurology for the Next Decade**



September 2-3, 2025 | Club University Foundation



Co-funded by the European Union. Views and opinions expressed are however those of the author(s) only and do not necessarily reflect those of the European Union or the European Health and Digital Executive Agency (HaDEA). Neither the European Union nor the granting authority can be held responsible for them.




Prof. Philippe Amouyel

Public Health Department Lille University

Hospital Fondation Alzheimer



EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE



Context

Neuro-oncology Neurovascular diseases Epilepsy Neurocognitive diseases
Neurogenetic diseases TBI Parkinson Multiple sclerosis

Neurological Diseases




Research -> Translation -> Clinic

Clinical symptoms Genomics Proteomics Transcriptomics Electronic Medical
Neuropsychological symptoms Metagenomics Metabolomics Records



EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE



SWOT ANALYSIS

Strengths



Weaknesses


Fragmentation of 27 countries
Lack of scientific strategic investments
UK outside of EU
Weak AI implementation among european physicians and scientists

Opportunities




Threats

Economical crisis
Tariffs
Unstability
Dependence on non european countries for hightech




Genomics of AD – European cohorts



EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE

Bellenguez, C. et al. New insights into the genetic etiology of Alzheimer's disease and related dementias. *Nat Genet* 54, 412–436 (2022) and Mega-meta: Consensus meta-analysis of genome-wide association studies for Alzheimer's disease and related dementia. *Nat Genet* (under revision)



JPND 2011–2025 publications



2,657 publications from WOS corecollection

1019 in Neurosciences

781 in Clinical Neurology

265 in Biochemistry and Molecular Biology

213 in Cell Biology

202 in Multidisciplinary Sciences

197 in Psychiatry

187 in Geriatrics Gerontology


91 in Genetics Heredity

87 in Medicine Research Experimentation

61 in Chemistry Multidisciplinary




EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE



JPND 2011–2025 citations

Times Cited and Publications Over Time



EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE

JPND 2019–2023 innovation



8 patent applications

OligoFIT, PMI-AD, NeuroPhage, Iron, Sleep, NIPARK, DynaSti, ORGTHERAPY and DIPPA-FTD



5 licenses granted on IP rights

PDWALK, PMI-AD, IronSleep, EU-FINGERS and SORLA-FIX



9 patents pending examination

PDWALK, OligoFIT, PMI-AD, DEBBIE, NeuroPhage, Iron Sleep, DynaSti, PREADAPT and ORGTHERAPY



2 licensed in or acquired a patent owned by another Organization

IronSleep and NEURIPIDES



EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE



LIGUE NATIONALE
ALZHEIMER LIGA
ASBL / VZW / VOG



Alzheimer
Society
CANADA



ONWARD



AstraZeneca




Key Issues to be tackled *(not only for PrecisionNeurology)*

- Reintegrate the UK into the European medical and scientific community.
 - Continue reducing fragmentation among European countries.
 - Invest in a European sovereign cloud for medical data. Invest in European AI companies developing tools to analyze this data.
- Increase the budget for the upcoming European Brain Health Partnership (starting January 1, 2026).



EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE







One Actionable Policy Recommendation

Invest in a European
sovereign cloud for
medical data



EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE





« It is far more important to know what person has the disease than what disease the person has » (attributed to Hippocrates)



EUROPEAN ALLIANCE
FOR PERSONALIZED MEDICINE

